KALV KalVista Pharmaceuticals
- 12.130
- -0.040-0.33%
KalVista Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
KalVista Pharma Analyst Ratings
KalVista Pharma Analyst Ratings
Buy Rating on KalVista Pharmaceuticals Backed by Sebetralstat's Breakthrough in HAE Treatment
KalVista Pharma Analyst Ratings
Buy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial Position
Buy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista Pharmaceuticals
Analysts' Top Healthcare Picks: KalVista Pharmaceuticals (KALV), Allakos (ALLK)
Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and KalVista Pharmaceuticals (KALV)
KalVista Pharma Analyst Ratings
Buy Rating and Increased Price Target for KalVista Pharmaceuticals Following Sebetralstat's Clinical Triumphs
Leerink Partners Sticks to Its Buy Rating for KalVista Pharmaceuticals (KALV)
Optimism Intact for KalVista Pharmaceuticals Despite Delay in KONFIDENT Study Data: Outperform Rating Reaffirmed
Positive Outlook for KalVista Pharmaceuticals With Buy Rating Reiterated Ahead of Phase 3 Study Results
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), KalVista Pharmaceuticals (KALV) and Cue Biopharma (CUE)
Jefferies Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $16 Price Target
KalVista Pharma Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Bioxcel Therapeutics (BTAI), KalVista Pharmaceuticals (KALV)
KalVista Pharma Analyst Ratings
Analysis
Price Target
No Data
